User:Tsui.a/Dostarlimab

Cancers that are mismatch-repair deficient are highly responsive to PD-1 blocking agents such as Dostarlimab. However, the duration of response is unknown and requires further follow-up studies.

Warning and precautions section:

In a study with 290 individuals with advanced EC who underwent treatment with Dostarlimab, follow up was evaluated after about a year regarding drug-related adverse events. The most commonly reported was fatigue, followed by diarrhea and nausea. There were no deaths associated with Dostarlimab treatment.

Pregnancy and Lactation
Dostarlimab can cause harm to a fetus. Individuals of childbearing potential should get a pregnancy test before starting treatment with Dostarlimab and use contraception during and for 4 months after treatment. Data is not currently available regarding the presence of Dostarlimab in breastmilk, so it is best to avoid breastfeeding during and for 4 months after treatment as well.

Research
The phase I GARNET trial proved significant clinical benefit without reducing quality of life, achieving accelerate approval for Dostarlimab. Randomized studies have yet to be conducted as of February 2022, but Dostarlimab remains the treatment of choice for patients with progressing advanced dMMR endometrial cancer after a platinum-containing regimen based on the GARNET trial.